BackErasca Overview
Erasca Inc

Erasca Target Price

Analysts' average 12-month price target for Erasca is $21.

Get informed when a big investor buys or sells

+ Follow

Share Price

$17.88

Average Target Price

$21.4319.8% upside

7 analysts in the last 4 months

High: $26 | Low: $16

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-13GuggenheimMichael Schmidt$2117.4% upsideOpen
2026-08-12H.C. Wainwright$2223% upsideOpen
2026-07-20Morgan Stanley$2117.4% upsideOpen
2026-07-14Jefferies$2434.2% upsideOpen
2026-07-14HSBC$2011.9% upsideOpen
2026-06-04Wolfe Research$1610.5% downsideOpen
2026-05-12Mizuho Securities$2645.4% upsideOpen
2026-04-27Stifel Nicolaus$3067.8% upsideOpen
2026-03-10Stifel NicolausLaura Prendergast$2011.9% upsideOpen
2026-01-27Guggenheim$1232.9% downsideOpen
2026-01-26Morgan StanleySean Laaman$1044.1% downsideOpen
2026-01-16Piper Sandler$1138.5% downsideOpen
2026-01-12Stifel NicolausLaura Prendergast$1044.1% downsideOpen
2026-01-08Morgan Stanley$477.6% downsideOpen
2026-01-07Piper Sandler$572% downsideOpen
2025-12-09Mizuho Securities$572% downsideOpen
2025-11-06Stifel Nicolaus$666.4% downsideOpen
2025-10-15Stifel NicolausLaura Prendergast$477.6% downsideOpen
2025-05-14GuggenheimMichael Schmidt$383.2% downsideOpen
2025-03-26Raymond JamesLaura Prendergast$572% downsideOpen
2024-11-18JefferiesMaury Raycroft$666.4% downsideOpen
2024-04-01Goldman SachsChris Shibutani$760.9% downsideOpen

Erasca (ERAS) FAQ

Erasca's target price stands at $21. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $21 for ERAS implies 19.8% upside versus today's price ($17.88). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Erasca's target price evolved across reporting periods, while the comparison chart places ERAS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Erasca's reading of $21 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.